Patents by Inventor Evan M. Hersh

Evan M. Hersh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SYNERGISTIC ANTI-CANCER COMPOSITIONS
    Publication number: 20080153891
    Abstract: The present invention provides compositions useful in treating cancer. The compositions include a synergistic combination of an antineoplastic thiol-binding mitochondrial oxidant with an antineoplastic nucleic acid binding agent, an antineoplastic antimetabolite base analog, or docetaxel. Also provided are methods of assaying the synergistic effects of the combinations and methods of treating cancer using the synergistic combinations.
    Type: Application
    Filed: December 6, 2007
    Publication date: June 26, 2008
    Applicant: The Arizona Board of Regents
    Inventors: Robert T. DORR, David S. Alberts, Evan M. Hersh
  • SYNERGISTIC ANTI-CANCER COMPOSITIONS
    Publication number: 20080146653
    Abstract: The present invention provides compositions useful in treating cancer. The compositions include a synergistic combination of an antineoplastic thiol-binding mitochondrial oxidant with an antineoplastic nucleic acid binding agent, an antineoplastic antimetabolite base analog, or docetaxel. Also provided are methods of assaying the synergistic effects of the combinations and methods of treating cancer using the synergistic combinations.
    Type: Application
    Filed: December 6, 2007
    Publication date: June 19, 2008
    Applicant: The Arizona Board of Regents
    Inventors: Robert T. DORR, David S. Alberts, Evan M. Hersh
  • Cyanoaziridines for treating cancer
    Patent number: 6297230
    Abstract: The present invention is directed to novel anti-cancer compounds of the formula. wherein X is CN, R4 is hydrogen or lower alkyl; and R5 is lower alkyl, lower cycloalkyl, alkenyl, alkynyl, aryl, monosubstituted aryl, disubstituted aryl, aryl lower alkyl, lower alkoxycarbonyl lower alkyl, or heterocyclic ring, with the proviso that when X is CN, and R4 is hydrogen, then R5 is not CH3, C6H5, or, p-nitrophenyl. R4, R5 and N taken together form a heterocyclic ring.
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: October 2, 2001
    Assignee: Amplimed, Inc.
    Inventors: William A. Remers, Evan M. Hersh, Robert T. Dorr, Bhashyam Iyengar
  • Monoclonal antibodies specific for HIV and hybridomas for their production
    Patent number: 5445960
    Abstract: Human IgG1 monoclonal antibodies are produced by hybridoma ATCC HB10074 and bind to gp120 of HIV.
    Type: Grant
    Filed: May 24, 1993
    Date of Patent: August 29, 1995
    Assignees: The Arizona Board of Regents on behalf of the University of Arizona, Teijin Limited
    Inventors: Yasuhiko Masuho, Toru Sugano, Yoh-Ichi Matsumoto, Evan M. Hersh, Eskild A. Petersen, Douglas Lake, Takashi Kawamura
  • Human hybridomas and monoclonal antibodies which bind both gp41 and gp120 envelope proteins of human immunodeficiency virus
    Patent number: 5298419
    Abstract: The invention is directed to the human hybridoma designated MCA 86 and having A.T.C.C. Accession No. HB 9669 and human monoclonal antibodies produced by hybridoma MCA 86. Human monoclonal antibodies produced by hybridoma MCA 86 immunologically binds to both gp41 and gp120 envelope glycoproteins of Human Immunodeficiency Virus (HIV). These monoclonal antibodies are useful in the diagnosis of HIV infection.
    Type: Grant
    Filed: March 31, 1988
    Date of Patent: March 29, 1994
    Assignees: The Arizona Board of Regents on behalf of the University of Arizona, Teijin Limited
    Inventors: Yasuhiko Masuho, Toru Sugano, Yoh-ichi Matsumoto, Evan M. Hersh, Eskild A. Peterson
  • Interferon antibody therapeutic compositions having an extended serum half-life
    Patent number: 5055289
    Abstract: A complex of alpha-interferon with a monoclonal antibody complexes with the alpha-interferon without impairing its antiviral activity. The serum half-life of the interferon administered as the complex is substantially increased when compared to that of alpha-interferon administered alone.
    Type: Grant
    Filed: August 19, 1988
    Date of Patent: October 8, 1991
    Assignee: Hybritech Incorporated
    Inventors: James M. Frincke, Barbara W. Unger, Karen G. Burnett, Evan M. Hersh, Michael G. Rosenblum, Jordan U. Gutterman
  • Composition and method for treatment of disseminated fungal infections in mammals
    Patent number: 4978654
    Abstract: A method is disclosed for treatment of disseminated fungal infection in a mammal comprising the administration of a fungicidally effective amount of Amphotericin B encapsulated in a substantially sterol-free liposome to the infected mammal. Also provided is an agent for treatment of disseminated fungal infection in a mammal comprising Amphotericin B encapsulated in a liposome which consists essentially of lipids other than sterols.
    Type: Grant
    Filed: January 12, 1987
    Date of Patent: December 18, 1990
    Assignee: Board of Regents, The University of Texas System
    Inventors: Gabriel Lopez-Berestein, Victor Fainstein, Evan M. Hersh, Roy L. Hopfer, Rudolph L. Juliano, Kapil Mehta, Reeta Mehta
  • Composition and method for treatment of disseminated fungal infections in mammals
    Patent number: 4663167
    Abstract: Method for treatment of disseminated fungal infection in a mammal comprising the administration of a fungicidally effective amount of Amphotericin B encapsulated in a substantially sterol-free liposome to the infected mammal. Also provided is an agent for treatment of disseminated fungal infection in a mammal comprising liposome-encapsulated Amphotericin B, said liposome being comprised of lipids other than sterols.
    Type: Grant
    Filed: April 16, 1984
    Date of Patent: May 5, 1987
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Gabriel Lopez-Berestein, Victor Fainstein, Evan M. Hersh, Roy L. Hopfer, Rudolph L. Juliano, Kapil Mehta, Reeta Mehta